Skip to content
lifestyle.digitaladblog.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Ipsen Pharma
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
April 22, 2026
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
March 18, 2026
Ipsen appoints Michelle C. Werner as EVP, President of North America
March 12, 2026
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
March 9, 2026
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
February 27, 2026
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
February 13, 2026
←
Previous Page
1
2